Question explored with the scientific record
Conversation so far
- 1 Is ivermectin effective in fighting cancer
- 2 Where there is no evidence of familial history what are the likely causes of prostate cancer
- 3 What are the documented risks relating to hifu treatment of the prostate cancer with a 4+3 geelong score
- 4 What are the documented risks relating to hifu treatment of the prostate cancer confined to the prostate capsule
- 5 How often is a second treatment needed after HIFU if biopsy stays positive?
- 6 Is hifu less impacting on the body compared to radiation and hormone therapy?
Answered on this page ↓
Is hifu less impacting on the body compared to radiation and hormone therapy?
The short version: on tissue damage, HIFU looks gentler than radiation or hormone therapy, but the retrieved records do not put the three head to head.
HIFU burns only the prostate from outside the body, so it spares surrounding tissue [1][2]. Radiation, by contrast, carries real collateral damage: late bowel and urinary side effects were more common with the shorter radiation schedule [3][4], and prostate radiation raised the later risk of rectal cancer compared with surgery [7]. Hormone therapy is a body-wide drug, and it is the one with the clearest systemic toll: higher diabetes and heart-attack risk on GnRH agonists [6], plus muscle and bone loss [6][5].
| Therapy | Main systemic or collateral harm | Source |
|---|---|---|
| HIFU | Fistula, stricture, incontinence to nearby organs | [2] |
| Radiation | Late bowel and urinary side effects; later rectal cancer risk | [3][7] |
| Hormone therapy | Diabetes, heart attack, bone loss | [6][5] |
The catch is that HIFU's own harms are local and sometimes severe: rectourethral fistula, bladder outlet obstruction, and stress incontinence [2]. None of the records compare all three on hard outcomes like survival. No trial here settles which is least harmful for your cancer.
My call: HIFU is plausibly the least systemically toxic, but the evidence is indirect. Confidence: low.
Sources used 7
-
High-Intensive Focused Ultrasound in Localized Prostate Cancer
This study evaluates transrectal high-intensity focused ultrasound (HIFU) using the Ablatherm device as a minimally invasive local therapy for localized prostate cancer in 65 men, reporting safety, selective vs global tumor ablation outcomes, PSA kinetics, biopsy results, and po…
DOI: 10.1089/end.2000.14.293 -
Applications of High-Intensity Focused Ultrasound in the Treatment of Different Pathologies
Comprehensive literature review of high-intensity focused ultrasound across multiple pathologies demonstrates general safety and feasibility as a noninvasive ablative option, with high but disease-variable reported success and a need for larger, standardized human trials.
DOI: 10.1177/8756479320972086 -
Randomized Phase III Noninferiority Study Comparing Two Radiotherapy Fractionation Schedules in Patients With Low-Risk Prostate Cancer
This study demonstrates that a hypofractionated radiotherapy schedule (70 Gy in 28 fractions over 5.6 weeks) is not inferior to a conventional schedule (73.8 Gy in 41 fractions over 8.2 weeks) in terms of disease-free survival for men with low-risk prostate cancer, although it i…
DOI: 10.1200/JCO.2016.67.0448 -
Randomized Phase III Noninferiority Study Comparing Two Radiotherapy Fractionation Schedules in Patients With Low-Risk Prostate Cancer
In men with low-risk prostate cancer, hypofractionated radiotherapy (70 Gy/28 fractions) was noninferior to conventional radiotherapy (73.8 Gy/41 fractions) for 5-year disease-free survival, despite increased late grade 2-3 GI and GU adverse events.
DOI: 10.1200/jco.2016.67.0448 -
Update on the management of prostate cancer with goserelin acetate: patient perspectives
A narrative review summarizing how androgen deprivation therapy (ADT) with goserelin acetate has evolved for prostate cancer over the past five years, outlining patient-centered perspectives, the benefits and risks, and current guidance on when ADT should or should not be used.
DOI: 10.2147/CMAR.S5058 -
Metabolic Complications and Increased Cardiovascular Risks as a Result of Androgen Deprivation Therapy in Men with Prostate Cancer
This narrative review synthesizes evidence that androgen deprivation therapy (ADT) for prostate cancer is associated with metabolic complications—insulin resistance, diabetes, dyslipidemia, and adverse body composition—and increased cardiovascular risk.
DOI: 10.1155/2011/391576 -
Radiation Therapy for Prostate Cancer Increases the Risk of Subsequent Rectal Cancer
This study investigates the increased risk of subsequent rectal cancer in men treated with radiation therapy for prostate cancer compared to those treated surgically, revealing a significant rise in risk and poorer outcomes for rectal cancer diagnosed post-radiation.
DOI: 10.1097/SLA.0b013e3182382fd5